FXYD3 functionally demarcates an ancestral breast cancer stem cell subpopulation with features of drug-tolerant persisters
Mengjiao Li, Noriko Gotoh(The University of Tokyo), Yasuto Takeuchi(Kanazawa University), Teppei Shimamura(Nagoya City University), Koji Okamoto(Teikyo University), Arinobu Tojo(University of Tokyo Hospital), Daisuke Shiokawa(Tokyo University of Science), Chia‐Chi Liu(University of Technology Sydney), Masafumi Inokuchi(Kanazawa University Hospital), Masahiko Tanabe(The University of Tokyo), Seitaro Nomura(The University of Tokyo), Toshinari Yamashita(Kanagawa Prefectural Hospital Organization), Luís Augusto Eijy Nagai(Quantitative BioSciences), Seishi Ogawa(Kyoto University), Masahiro Nakagawa(Columbia University Irving Medical Center), Yutaka Suzuki(Frontier Medical College), Sumio Sugano(The University of Tokyo), Dominic Chih‐Cheng Voon(National University of Singapore), Keiichiro Tada(Nihon University), Theodoros Foukakis(Karolinska University Hospital), Shinya Sato(Nagoya City University), Hiroshi Asahara(Scripps Research Institute), Tatsunori Nishimura, Tomoki Chiba(Tokai University), Akinori Kanai(Frontier Medical College), Satoko Ishikawa(Kanazawa University Hospital), Manami Katoh(University of Tokyo Hospital), Yohei Miyagi(Kanagawa Prefectural Hospital Organization), Tetsu Akiyama(The University of Tokyo), Ryuichiro Nakato(Quantitative BioSciences), Haruka Hirose(Nagoya City University), Tsunaki Hongu(German Cancer Research Center), Kang Wang(Karolinska University Hospital), Yuming Wang(Shanghai Jiao Tong University), Xi Cheng(University of Notre Dame), Tetsuo Ota(Kanazawa University Hospital), Asako Sasahara(The University of Tokyo), Masao Yano(Oida Hospital), Y. UCHIDA(Systems Biology Institute)
Cited by 29
Related Papers
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.7k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k